B. Riley Securities Reiterates Buy on Trevi Therapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has reiterated its Buy rating on Trevi Therapeutics, maintaining a price target of $6.
October 07, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B. Riley Securities has reiterated its Buy rating on Trevi Therapeutics, maintaining a price target of $6. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $6 price target by B. Riley Securities indicates a positive outlook on Trevi Therapeutics' stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100